Special Issue

A 'One-Health Focus' on Natural Aquatic Toxins

Message from the Guest Editors

Natural aquatic toxins are produced naturally by certain species of algae and bacteria in a wide range of aquatic environments and may subsequently accumulate in aquatic foodstuffs such as shellfish and fish, causing significant global risk to consumers. In addition, toxins are known to impact directly and indirectly upon both animal and ecosystem health. Different toxin groups exist, many of which are regulated to ensure consumer protection, although in recent years other groups have emerged, causing varying degrees of hazard and associated human health risks. Given the number and complexity of toxin congeners potentially associated with each toxin class, and notable differences in relative toxicity and modes of action, there is a continuing need to assess the developing threats from marine shellfish and fish toxins. With the increase in new toxin findings and exposure pathways over the last five years, this Special Issue of Marine Drugs is taking a "One-Health" focus on recent advances in marine and freshwater shellfish toxin research, which cause impacts on human, animal, and environmental health.

Guest Editors

Dr. Andrew Turner

Centre for Environment, Fisheries and Aquaculture Science, Weymouth Laboratory, Lowestoft, UK

Dr. Alison Robertson

Marine Toxicology & Chemistry, Department of Marine Sciences, University of South Alabama, Mobile, AL 36688, USA

Deadline for manuscript submissions

closed (10 May 2020)



Marine Drugs

an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



mdpi.com/si/35562

Marine Drugs Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 marinedrugs@mdpl.com

mdpi.com/journal/marinedrugs





an Open Access Journal by MDPI

Impact Factor 5.4 CiteScore 10.1 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

